play_arrow

keyboard_arrow_right

skip_previous play_arrow skip_next
00:00 00:00
playlist_play chevron_left
volume_up
chevron_left
play_arrow

Featured

PLUS Study

Dr Swapnil Pawar February 8, 2022 261


Background
share close
  • cover play_arrow

    PLUS Study
    Dr Swapnil Pawar

Join us for our 90th episode of the eCritCare podcast, where Jose Chacko & I discuss the recently published landmark trial PLUS. This trial demonstrated no significant difference in 90-day mortality between the saline group and the plasmalyte-148 group.

It raises the question – Does the choice of IV fluid in ICU really matter?

Should we stop worrying about the choice of fluid and focus on not giving so-called “maintenance fluids” to critically ill patients?

The key message is “anything in excess is bad, don’t give something that patient doesn’t need.”

Rate it
Previous episode
eCritCare Podcast
play_arrow
share playlist_add
close
  • 152

Featured

MICHELLE Trial – Rivaroxaban in COVID-19

Dr Swapnil Pawar January 30, 2022

play_arrow MICHELLE Trial – Rivaroxaban in COVID-19 Dr Swapnil Pawar Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial Blog Written […]

Read more trending_flat